Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which finger or earlobe? a study tests the best spot for oxygen monitoring in lung disease

NCT ID NCT07723872

Knowledge-focused Sponsor: Hospital de Granollers Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This study compares oxygen readings taken from the finger and the earlobe during a six-minute walk test in people with interstitial lung disease. The goal is to see if one location gives more accurate measurements of oxygen levels during exercise. The results could help doctors decide where to place the sensor for better monitoring and treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If earlobe readings prove more reliable, it could lead to better oxygen monitoring and more accurate treatment decisions for people with interstitial lung disease.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly improve health. The findings may not change current practice if the difference between sensor locations is small.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Consecutive adults with a confirmed diagnosis of interstitial lung disease (ILD), either newly diagnosed or under follow-up, attending the ILD/pulmonary fibrosis units of the participating centres and undergoing a clinically indicated 6-minute walk test. Patients with or without prior oxygen therapy are enrolled consecutively, and baseline oxygen status (none, exertional only, or at rest) is recorded. Each patient is assessed on a single occasion, consistent with the cross-sectional design.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older * Confirmed diagnosis of interstitial lung disease (ILD) based on clinical, radiological and/or histological criteria * Newly diagnosed or under follow-up for ILD * Physically and cognitively able to perform the 6-minute walk test (6MWT) * Signed informed consent Exclusion Criteria: * Inability to obtain a reliable, stable baseline pulse oximetry reading at the finger and/or the earlobe, preventing a valid paired baseline measurement and the calculation of agreement * ILD exacerbation, decompensated comorbidity, or acute respiratory infection at the time of the test

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Connective tissue disease-associated interstitial lung disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic pulmonary fibrosis interstitial lung disease pulmonary fibrosis systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Connective tissue disease-associated interstitial lung disease Idiopathic pulmonary fibrosis (IPF) Interstitial lung disease (ILD) Interstitial lung disease due to connective tissue disease (disorder) Progressive pulmonary fibrosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hospital de Granollers

    RECRUITING

    Granollers, Spain, 08402, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.